Intravenous Iron Drugs Market Size, Share, and Trends 2024 to 2034

Intravenous Iron Drugs Market (By Product: Iron Sucrose, Iron Dextran, Ferric Carboxymaltose; By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Disease) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034

  • Last Updated : July 2024
  • Report Code : 4055
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Intravenous Iron Drugs Market 

5.1. COVID-19 Landscape: Intravenous Iron Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Intravenous Iron Drugs Market, By Product

8.1. Intravenous Iron Drugs Market Revenue and Volume, by Product, 2024-2034

8.1.1. Iron Sucrose

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Iron Dextran

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Ferric Carboxymaltose

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global Intravenous Iron Drugs Market, By Application

9.1. Intravenous Iron Drugs Market Revenue and Volume, by Application, 2024-2034

9.1.1. Chronic Kidney Disease

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Inflammatory Bowel Disease

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Cancer

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

9.1.4. Other Disease

9.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global Intravenous Iron Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.1.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.2.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.3.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.4.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.5.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)

10.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)

Chapter 11. Company Profiles

11.1. Allergan Plc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. AMAG Pharmaceuticals, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Daiichi Sankyo, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Luitpold Pharmaceuticals, Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. American Regent, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Pharmacosmos A/S

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Sanofi US

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Vifor Pharma Ltd.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client